Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PostScript

Letter

Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases

Online download statistics by month:

Online download statistics by month: September 2021 to August 2024

	Abstract	Full	Pdf
Sep 2021	39	17	12
Oct 2021	260	4	0
Nov 2021	343	3	2
Dec 2021	234	1	0
Jan 2022	232	4	2
Feb 2022	147	1	1
Mar 2022	298	0	0
Apr 2022	236	0	0
May 2022	216	2	1
Jun 2022	239	9	3
Jul 2022	209	2	0
Aug 2022	231	3	0
Sep 2022	222	3	1
Oct 2022	214	3	1
Nov 2022	181	1	0
Dec 2022	379	8	3
Jan 2023	418	4	4
Feb 2023	298	4	5
Mar 2023	94	4	3
Apr 2023	76	1	1
May 2023	55	0	0
Jun 2023	54	2	2
Jul 2023	54	0	0
Aug 2023	95	1	1
Sep 2023	100	0	1
Oct 2023	67	0	0
Nov 2023	82	3	1
Dec 2023	78	2	2
Jan 2024	18	1	3
Feb 2024	51	1	1
Mar 2024	84	5	3
Apr 2024	54	4	4
May 2024	46	1	0
Jun 2024	56	2	3
Jul 2024	29	2	2
Aug 2024	46	2	1
Total	5535	100	63